RRPV Solicitation Summary: Rapid Antigen Production for Immunoassay Diagnostics (RAPID)

The Administration for Strategic Preparedness and Response, specifically the Biomedical Advanced Research and Development Authority (BARDA), issued this special notice for the Rapid Antigen Production for Immunoassay Diagnostics (RAPID) project. Managed through the Rapid Response Partnership Vehicle (RRPV) Consortium, the initiative supports advanced research and development for protein-based molecular recognition reagent generation platforms. The primary objective is to establish flexible, end-to-end systems capable of producing high-performance binders against known and emerging biological threats. The program aims to significantly compress development timelines, ideally reaching assay-ready reagents from a pathogen sequence within weeks.

This requirement is identified under NAICS code 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC AN42 for HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH. There is no set-aside designated for this opportunity. Interested parties may participate in a virtual Proposer’s Conference and Teaming Connect scheduled for April 27, 2026. The solicitation includes one attachment regarding the solicitation site, and the point of contact for the notice is Rebecca Harmon.

The response deadline for solicitation number RRPV-RPP-26-10-RAPID is May 13, 2026. Full proposal details, registration for the conference, and consortium joining instructions are provided through the RRPV website. This notice was published and last updated on April 15, 2026.